SensoDetect Aktiebolag Valuation

Is SDET undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SDET when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SDET (SEK0.12) is trading below our estimate of fair value (SEK0.14)

Significantly Below Fair Value: SDET is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SDET?

Key metric: As SDET is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SDET. This is calculated by dividing SDET's market cap by their current revenue.
What is SDET's PS Ratio?
PS Ratio	15.8x
Sales	SEK 2.26m
Market Cap	SEK 35.71m

SDET key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	15.8x
Enterprise Value/EBITDA	-6.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does SDET's PS Ratio compare to its peers?

The above table shows the PS ratio for SDET vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.1x
CRBX Carbiotix	10.6x	n/a	SEK 34.6m
PLUN ProstaLund	1.8x	n/a	SEK 29.7m
FLUI Fluicell	5.9x	n/a	SEK 28.4m
PERP B Perpetua Medical	1.9x	n/a	SEK 22.6m
SDET SensoDetect Aktiebolag	15.8x	n/a	SEK 35.7m

Price-To-Sales vs Peers: SDET is expensive based on its Price-To-Sales Ratio (15.8x) compared to the peer average (6.9x).

Price to Sales Ratio vs Industry

How does SDET's PS Ratio compare vs other companies in the SE Medical Equipment Industry?

12 Companies	Price / Sales	Estimated Growth	Market Cap
ARJO B Arjo	0.8x	3.7%	US$844.23m
CARE Careium	0.8x	10.2%	US$64.16m
BOUL Boule Diagnostics	0.5x	6.4%	US$24.72m
ARCOMA Arcoma	0.9x	8.3%	US$13.37m

12 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: SDET is expensive based on its Price-To-Sales Ratio (15.8x) compared to the Swedish Medical Equipment industry average (4.8x).

Price to Sales Ratio vs Fair Ratio

What is SDET's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SDET PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	15.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SDET's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Arcoma

SEK 146.4m

Develops, produces, and provides radiology solutions worldwide.

ARCOMA

SEK 11.15

6.2%

53.8%

Mentice

SEK 560.0m

Provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas.

MNTC

SEK 22.80

8.6%

-44.7%

Dignitana

SEK 95.8m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.23

11.8%

-42.8%